以科学和风险为基础的稳定性战略,支持产品生命周期的变化。

IF 5 3区 医学 Q1 PHARMACOLOGY & PHARMACY
Lori McCaig, Steven Nowak, Alexander Abbott, Jenny Carhart, Megan E McMahon, Elke Debie, Hanlin Li, Francis Maina, Andrea J Ji, Mingkun Fu, Yan Wu, Andrew Lennard, Tony Mazzeo, Chad Wolfe, Robert Timpano, Yelizaveta Babayan, Lars Gruenig
{"title":"以科学和风险为基础的稳定性战略,支持产品生命周期的变化。","authors":"Lori McCaig, Steven Nowak, Alexander Abbott, Jenny Carhart, Megan E McMahon, Elke Debie, Hanlin Li, Francis Maina, Andrea J Ji, Mingkun Fu, Yan Wu, Andrew Lennard, Tony Mazzeo, Chad Wolfe, Robert Timpano, Yelizaveta Babayan, Lars Gruenig","doi":"10.1208/s12248-024-00903-z","DOIUrl":null,"url":null,"abstract":"<p><p>ICH Q12 asserts that science- and risk-based approaches are applicable to stability studies supporting Chemistry, Manufacturing and Controls (CMC) post-approval changes (PAC) to enable more timely implementation; however, no guidance or specific examples are provided to demonstrate how prior knowledge of the product can inform the risk assessment for the proposed change(s). Ten diverse case studies are presented in this manuscript to demonstrate how science- and risk-based stability strategies were used to support drug substance and product CMC PAC and lifecycle management activities. The accumulated stability knowledge held by original manufacturers of marketed products is substantial, and different elements of this knowledge base were used to assess the risks and impact of the proposed changes for confident change management. This paper provides ways to leverage science- and risk-based stability strategies as part of the post-approval change-management risk-mitigation strategy, which may enable a reduced stability data commitment and/or a reduced reporting category for change implementation.</p>","PeriodicalId":50934,"journal":{"name":"AAPS Journal","volume":"26 2","pages":"34"},"PeriodicalIF":5.0000,"publicationDate":"2024-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes.\",\"authors\":\"Lori McCaig, Steven Nowak, Alexander Abbott, Jenny Carhart, Megan E McMahon, Elke Debie, Hanlin Li, Francis Maina, Andrea J Ji, Mingkun Fu, Yan Wu, Andrew Lennard, Tony Mazzeo, Chad Wolfe, Robert Timpano, Yelizaveta Babayan, Lars Gruenig\",\"doi\":\"10.1208/s12248-024-00903-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ICH Q12 asserts that science- and risk-based approaches are applicable to stability studies supporting Chemistry, Manufacturing and Controls (CMC) post-approval changes (PAC) to enable more timely implementation; however, no guidance or specific examples are provided to demonstrate how prior knowledge of the product can inform the risk assessment for the proposed change(s). Ten diverse case studies are presented in this manuscript to demonstrate how science- and risk-based stability strategies were used to support drug substance and product CMC PAC and lifecycle management activities. The accumulated stability knowledge held by original manufacturers of marketed products is substantial, and different elements of this knowledge base were used to assess the risks and impact of the proposed changes for confident change management. This paper provides ways to leverage science- and risk-based stability strategies as part of the post-approval change-management risk-mitigation strategy, which may enable a reduced stability data commitment and/or a reduced reporting category for change implementation.</p>\",\"PeriodicalId\":50934,\"journal\":{\"name\":\"AAPS Journal\",\"volume\":\"26 2\",\"pages\":\"34\"},\"PeriodicalIF\":5.0000,\"publicationDate\":\"2024-03-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"AAPS Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1208/s12248-024-00903-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"AAPS Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1208/s12248-024-00903-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

ICH Q12 规定,以科学和风险为基础的方法适用于支持化学、生产和控制 (CMC) 批准后变更 (PAC) 的稳定性研究,以便更及时地实施;但是,没有提供指导或具体示例来说明如何通过对产品的事先了解来为拟议变更的风险评估提供信息。本手稿介绍了十个不同的案例研究,以展示如何利用基于科学和风险的稳定性策略来支持药物和产品的 CMC PAC 和生命周期管理活动。已上市产品的原始生产商积累了大量稳定性知识,这些知识库中的不同元素被用于评估拟议变更的风险和影响,以便进行有把握的变更管理。本文介绍了如何利用以科学和风险为基础的稳定性策略,将其作为批准后变更管理风险缓解策略的一部分,从而减少稳定性数据承诺和/或减少变更实施的报告类别。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Science- and Risk-Based Stability Strategies to Support Product Lifecycle Changes.

ICH Q12 asserts that science- and risk-based approaches are applicable to stability studies supporting Chemistry, Manufacturing and Controls (CMC) post-approval changes (PAC) to enable more timely implementation; however, no guidance or specific examples are provided to demonstrate how prior knowledge of the product can inform the risk assessment for the proposed change(s). Ten diverse case studies are presented in this manuscript to demonstrate how science- and risk-based stability strategies were used to support drug substance and product CMC PAC and lifecycle management activities. The accumulated stability knowledge held by original manufacturers of marketed products is substantial, and different elements of this knowledge base were used to assess the risks and impact of the proposed changes for confident change management. This paper provides ways to leverage science- and risk-based stability strategies as part of the post-approval change-management risk-mitigation strategy, which may enable a reduced stability data commitment and/or a reduced reporting category for change implementation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
AAPS Journal
AAPS Journal 医学-药学
CiteScore
7.80
自引率
4.40%
发文量
109
审稿时长
1 months
期刊介绍: The AAPS Journal, an official journal of the American Association of Pharmaceutical Scientists (AAPS), publishes novel and significant findings in the various areas of pharmaceutical sciences impacting human and veterinary therapeutics, including: · Drug Design and Discovery · Pharmaceutical Biotechnology · Biopharmaceutics, Formulation, and Drug Delivery · Metabolism and Transport · Pharmacokinetics, Pharmacodynamics, and Pharmacometrics · Translational Research · Clinical Evaluations and Therapeutic Outcomes · Regulatory Science We invite submissions under the following article types: · Original Research Articles · Reviews and Mini-reviews · White Papers, Commentaries, and Editorials · Meeting Reports · Brief/Technical Reports and Rapid Communications · Regulatory Notes · Tutorials · Protocols in the Pharmaceutical Sciences In addition, The AAPS Journal publishes themes, organized by guest editors, which are focused on particular areas of current interest to our field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信